I

n a setback for Gilead Sciences (GILD), Ukrainian authorities have rejected a key patent for the Sovaldi hepatitis C treatment, according to patient advocacy groups that challenged the patent filing. The decision means that lower-cost generic versions of the medicine may become available by 2020, or a decade sooner than if the patent had been awarded.

“This is a very important achievement for Ukrainian patients,” says Sergiy Dmitriev of the All-Ukrainian Network of People Living with HIV, which filed the patent challenge. “Thanks to this decision, we expect that the price of medicines may drop three-fold, and for us, this means that three times more patients with hepatitis C will have access to modern drugs.”

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.